aibio
Debt Financing ·
Baxter raises note tender offer cap to $600 million after early results
Holders tendered $756,712,000 of the 2.539% notes due 2032 by the early tender time. The offer cap rose from $500 million to $600 million.
BAX Baxter International Inc.
Baxter International (BAX) news BAX class action, offering and merger news
Latest Baxter International news
- Legal
Baxter faces two securities class actions and a derivative suit over Novum LVP statements
Suits in Illinois federal court allege misleading statements about Baxter's Novum LVP pump. The 10-Q names Baxter and unnamed officers; the derivative captions name Jose E. Almeida.
- Legal
Baxter's Hillrom unit faces Linet antitrust suit, a bed-buyer appeal and two DOJ requests
Linet Americas sued Hill-Rom Holdings, Hill-Rom Company and Hill-Rom Services in 2021. A dismissed class action is on appeal, and a DOJ demand and subpoena remain open.
- Financings
Baxter closes three-series senior notes offering with about $1.99 billion in net proceeds
Baxter closed a three-series senior notes offering on December 4, 2025 and used part of the proceeds to repay its term loan. The rest is earmarked for cash tender offers on older notes, so the company is swapping debt rather than shrinking it.
- Mergers
Baxter completes Kidney Care business sale and receives about $3.71 billion in net cash proceeds
Baxter completed the sale of its Kidney Care business on January 31, 2025 and received about $3.71 billion in net, pre-tax cash at closing, against a $3.80 billion price set at signing. The price is still subject to post-closing adjustments, and executive Chris Toth stepped down on the closing date.
What Baxter International does
Baxter International provides essential healthcare products, including sterile intravenous solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. Its products are used in hospitals, nursing homes, ambulatory surgery centers, kidney dialysis centers, doctors' offices and at home under physician supervision. Baxter reports three segments: Medical Products & Therapies, Healthcare Systems & Technologies and Pharmaceuticals. It completed the sale of its Kidney Care business, now known as Vantive Health, to Carlyle on January 31, 2025, for an aggregate purchase price of $3.80 billion in cash. It sold its BioPharma Solutions business in 2023. Its innovation strategy focuses on connected care offerings, including smart bed systems, infusion pumps and patient monitoring, alongside core therapy products. Baxter manufactures products in over 20 countries and sells them in over 100 countries. Andrew Hider became president and chief executive officer in July 2025.
| Product or program | What it is | Stage |
|---|---|---|
| Sterile IV solutions | Intravenous solutions used in hospitals and at home | |
| Smart bed systems | Connected care beds in its Healthcare Systems & Technologies segment | |
| Parenteral nutrition therapies | Nutrition therapies given by injection or infusion | |
| Infusion systems and devices | Infusion pumps and administration sets | |
| Generic injectable pharmaceuticals | Injectable products in the Pharmaceuticals segment |
Baxter International annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $11.24 billion | $10.64 billion |
| Research and development | $518.0 million | $590.0 million |
| Net income (loss) | -$957.0 million | -$649.0 million |
| Cash from operations | $845.0 million | $1.02 billion |
| Cash and equivalents | $1.97 billion | $1.76 billion |
Questions about Baxter International
Is there a class action against Baxter International?
Our latest story on this, dated Jul 30, 2026: "Baxter faces two securities class actions and a derivative suit over Novum LVP statements". The story links the filing or release it is based on. Read the story.
Has Baxter International raised money recently?
Our latest story on this, dated Dec 4, 2025: "Baxter closes three-series senior notes offering with about $1.99 billion in net proceeds". The story links the filing or release it is based on. Read the story.
Is Baxter International involved in a merger or acquisition?
Our latest story on this, dated Aug 18, 2026: "Baxter raises note tender offer cap to $600 million after early results". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Baxter International?
Baxter International Inc. trades under the ticker BAX on NYSE.
Where is Baxter International listed?
Baxter International Inc. is listed on NYSE.
What is the SEC CIK of Baxter International?
The SEC Central Index Key (CIK) for Baxter International Inc. is 10456. Its filings are on SEC EDGAR.
How many shares does Baxter International have outstanding?
516,995,999 shares as of 2026-07-23, per the cover page of its 10-Q filed 2026-07-30.
Which country or territory is Baxter International listed under?
Our directory records Baxter International Inc. under United States.
What does Baxter International do?
Our directory classifies Baxter International Inc. as: Diversified pharmaceuticals/medtech. This is a directory classification, not a description of the pipeline.
What is the ISIN of Baxter International?
The ISIN recorded for Baxter International Inc. is US0718131099.
Does aibio.space cover Baxter International?
aibio.space lists Baxter International Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Baxter International incorporated?
SEC records list its state or country of incorporation as DE.
What does Baxter International develop?
Baxter International provides essential healthcare products, including sterile intravenous solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. Its products are used in hospitals, nursing homes, ambulatory surgery centers, kidney dialysis centers, doctors' offices and at home under physician supervision.
What is Sterile IV solutions from Baxter International?
Sterile IV solutions: Intravenous solutions used in hospitals and at home
What is Smart bed systems from Baxter International?
Smart bed systems: Connected care beds in its Healthcare Systems & Technologies segment
Investor discussion: Baxter International
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
- Distress
Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 2.02,5.02,8.01,9.01). Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). Source
- Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Baxter International Inc
- CIK
- 10456
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus (3841)
- US tickers
- BAX (NYSE)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- ONE BAXTER PARKWAY, DEERFIELD, IL, 60015
- Phone
- 2249482000
- Shares outstanding
- 516,995,999 as of 2026-07-23 (10-Q filed 2026-07-30)
Recent filings
Listing details
- Company
- Baxter International Inc.
- Ticker
- BAX
- Listing
- NYSE
- Country or territory
- United States
- Business scope
- Diversified pharmaceuticals/medtech
- ISIN
- US0718131099
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction